Novabridge Biosciences ADR
(NBP)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2022 | 06-2022 | 12-2021 | 06-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -363,526 | -156,292 | -365,870 | -166,725 | 72,170 |
| Depreciation Amortization | 9,253 | 5,026 | 5,357 | 2,158 | 3,545 |
| Other Working Capital | 80,040 | 8,440 | 61,908 | 30,792 | -36,879 |
| Other Operating Activity | 114,341 | 57,554 | 145,905 | 65,218 | 27,610 |
| Operating Cash Flow | $-159,892 | $-85,272 | $-152,700 | $-68,557 | $66,446 |
| Cash Flows From Investing Activities | |||||
| Net Acquisitions | 0 | N/A | 0 | N/A | -39,487 |
| Other Investing Activity | 66,459 | 74,550 | -114,114 | -59,069 | 8,544 |
| Investing Cash Flow | $66,459 | $74,550 | $-114,114 | $-59,069 | $-30,943 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 6,141 | 5,282 | 93,200 | 75,309 | 527,277 |
| Financing Cash Flow | $6,141 | $5,282 | $93,200 | $75,309 | $527,277 |
| Exchange Rate Effect | 56,429 | 33,399 | -20,207 | -10,986 | -16,344 |
| Beginning Cash Position | 510,879 | 526,064 | 746,756 | 737,041 | 182,879 |
| End Cash Position | 480,016 | 554,023 | 552,935 | 673,738 | 729,315 |
| Net Cash Flow | $-30,863 | $27,959 | $-193,821 | $-63,303 | $546,436 |
| Free Cash Flow | |||||
| Operating Cash Flow | -159,892 | -85,272 | -152,700 | -68,557 | 66,446 |
| Free Cash Flow | -159,892 | -85,272 | -152,700 | -68,557 | 66,446 |